Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by Northforce13on Dec 02, 2021 10:59am
133 Views
Post# 34189950

RE:RE:4 Quarter Trends in Absorica and Absorica +

RE:RE:4 Quarter Trends in Absorica and Absorica + "I expect about 1.5 cent per quarter gain in EPS due to this factor."

- Might want to check your math, maybe you meant 0.15 c/quarter...   It's not much of a factor, but it does show good management, which is of higher value than the actual savings amount in this case. 

"Once again, we saw  knee jerk over selling in Q3."

I think so too, the SP had risen so far so fast that it was normal to expect a weak quarter to do this, but it is much more than it feels like it should be.  My guess was 2.25 was a reasonable pullback to be expected, but even at that levels the stock was too cheap.  

Cash levels will also increase substantially in Q4 to nearly $1 per share.

"At some point, one of two moves will be made by Mull.

Either we use the cash hoard to acquire or we will be sold."

- My gut feeling is Mull will not sell unless the buyout offer was huge, like 5 or 6, which isn't likely to happen, buyers normally want to pay a small premium to the past 20 days trading price.  This is fortunate (in my opinion) for longs because it obviates the possibility that we get sold out for a low price.  
- Dunno what they will do with the cash, guess we will see what comes up.

Picked up 20k at 1.75 yesterday and had put in another bid for 20k at 1.66 late in the day when it declined further but didn't get any.

GLTA

<< Previous
Bullboard Posts
Next >>